Dengue Vaccine: Considerations before Rollout in Colombia

PLoS Negl Trop Dis. 2016 Jun 9;10(6):e0004653. doi: 10.1371/journal.pntd.0004653. eCollection 2016 Jun.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Colombia / epidemiology
  • Dengue / epidemiology*
  • Dengue / prevention & control*
  • Dengue Vaccines / adverse effects*
  • Dengue Vaccines / immunology*
  • Dengue Virus / classification*
  • Health Services Accessibility
  • Humans
  • Infant
  • Serogroup

Substances

  • Dengue Vaccines

Grant support

This work was supported by grants from Colciencias (1102-04-16376 and 1102-04-13042), the Gobernación de Santander (2007-068000-0070), and the Sistema General de Regalías, Fondo de Ciencia, Tecnología e Innovación co-financed by Sanofi Pasteur (BPIN # 2013-0001-00011-P2). CJVA was supported by a fellowship from the Labex EpiGenMed via the National Research Agency, Programme for Future Investment ANR-10-LABX-12-01 and the University of Montpellier. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript